27 January 2022 
EMA/CHMP/18383/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (initial authorisation) 
Paxlovid 
PF-07321332 / ritonavir 
On 27 January 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion, recommending the granting of a marketing authorisation for the medicinal product Paxlovid, 
intended for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require 
supplemental oxygen and who are at increased risk for progressing to severe COVID-19. 
The applicant for this medicinal product is Pfizer Europe MA EEIG. 
Detailed recommendations for the use of this product are described in the product information (PI), which 
is published in English here. 
The European public assessment report (EPAR) will be published after the marketing authorisation has 
been granted by the European Commission and will make this information available in all official European 
Union languages. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
